Structure-based design of potent Grb2-SH2 domain antagonists not relying on phosphotyrosine mimics

Biochemical and Biophysical Research Communications

Volumn 349, Issue 2, 2006, Pages 497-503

  Jiang, Sheng ^a   Li, Peng ^a   Peach, Megan L ^a   Bindu, Lakshman ^b   Worthy, Karen W ^b   Fisher, Robert J ^b   Burke Jr , Terrence R ^a   Nicklaus, Marc ^a   Roller, Peter P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

Cyclic peptides; d Alanine; G1TE analogs; Grb2 SH2 antagonist; Grb2 SH2 domain; Non phosphotyrosine; Tyrosine kinase

Indexed keywords

AMINO ACID; CYCLOPEPTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCINE; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2 ANTAGONIST; LEUCINE; PHOSPHOTYROSINE; PROTEIN G1TE; PROTEIN SH2; RAS PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN MODIFICATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; SOLID;

ALANINE; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; GRB2 ADAPTOR PROTEIN; HUMANS; INHIBITORY CONCENTRATION 50; MICE; PEPTIDES; PHOSPHOTYROSINE; PROTEIN BINDING; PROTEIN-TYROSINE KINASES; SRC HOMOLOGY DOMAINS;

EID: 33748434738     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.08.059     Document Type: Article

References (40)

1. Margolis B. The Grb family of SH2 domain proteins. Prog. Biophys. Mol. Biol. 62 (1994) 223-244
2. Xie Y., Pendergast A.M., and Hung M.C. Dominant-negative mutants of Grb2 induced reversal of the transformed phenotypes caused by the point mutation-activated rat HER-2/Neu. J. Biol. Chem. 270 (1995) 30717-30724
3. Tari A.M., Hung M.C., Li K., and Lopez-Berestein G. Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells. Oncogene 18 (1999) 1325-1332
4. Diwan B.A., Ramakrishna G., Anderson L.M., and Ramljak D. Overexpression of Grb2 in inflammatory lesions and preneoplastic foci and tumors induced by N-nitrosodimethylamine in Helicobacter hepaticus-infected and noninfected A/J mice. Toxicol. Pathol. 28 (2000) 548-554
5. Yip S.S., and Daly R.J. Up-regulation of the protein tyrosine phosphatase SHP-1 in human breast cancer and correlation with GRB2 expression. Int. J. Cancer. 88 (2000) 363-368
6. Pendergast A.M., Quilliam L.A., Cripe L.D., Bassing C.H., Dai Z., Li N., Batzer A., Rabun K.M., Der C.J., and Schlessinger J. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75 (1993) 175-185
7. Janes P.W., Daly R.J., de Fazio A., and Sutherland R.L. Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. Oncogene 9 (1994) 3601-3608
8. Machida K., and Mayer B.J. The SH2 domain: versatile signaling module and pharmaceutical target. BBA-Proteins Proteomics. 1747 (2005) 1-25
9. Muller G. Peptidomimetic SH2 domain antagonists for targeting signal transduction. Top. Curr. Chem. 211 (2001) 17-59
10. Fretz H., Furet P., Garcia-Echeverria C., Ruhuel J., and Schoepfer J. Structure-based design of compounds inhibiting Grb2-SH2 mediated protein-protein interactions in signal transduction pathways. Curr. Pharm. Des. 6 (2000) 1777-1796
11. Rahuel J., Gay B., Erdmann D., Strauss A., Garcia-Echeverria C., Furet P., Caravatti G., Fretz H., Schoepfer J., and Grutter M.G. Structural basis for specificity of Grb2-SH2 revealed by a novel ligand binding mode. Nat. Struct. Biol. 3 (1996) 586-589
12. Ogura K., Tsuchiya S., Terasawa H., Yuzawa S., Hatanaka H., Mandiyan V., Schlessinger J., and Inagaki F.J. Conformation of an Shc-derived phosphotyrosine-containing peptide complexed with the Grb2 SH2 domain. J. Biomol. NMR 10 (1997) 273-278
13. Ogura K., Tsuchiya S., Terasawa H., Yuzawa S., Hatanaka H., Mandiyan V., Schlessinger J., and Inagaki F. Solution structure of the SH2 domain of Grb2 complexed with the Shc-derived phosphotyrosine-containing peptide. J. Mol. Biol. 289 (1999) 439-445
14. Caravatti G., Rahuel J., Gay B., and Furet P. Structure-based design of a non-peptidic antagonist of the SH2 domain of GRB2. Bioorg. Med. Chem. Lett. 9 (1999) 1973-1978
15. Long Y.-Q., Yao Z.-J., Voigt J.H., Lung F.-D.T., Luo J.H., Burke T.R., King C.R., Yang D., and Roller P.P. Structural requirements for Tyr in the consensus sequence Y-E-N of a novel nonphosphorylated inhibitor to the Grb2-SH2 domain. Biochem. Biophys. Res. Commun. 264 (1999) 902-908
16. Ettmayer P., France D., Gounarides J., Jarosinski M., Martin M.-S., Rondeau J.-M., Sabio M., Topoil S., Weidmann B., Zurini M., and Bair K.W. Structural and conformational requirements for high-affinity binding to the SH2 domain of Grb2(1). J. Med. Chem. 42 (1999) 971-980
17. Shi Z.-D., Lee K., Liu H., Zhang M., Roberts L.R., Worthy K.M., Fivash M.J., Fisher R.J., Yang D., and Burke Jr. T.R. A novel macrocyclic tetrapeptide mimetic that exhibits low-picomolar Grb2 SH2 domain-binding affinity. Biochem. Biophys. Res. Commun. 310 (2003) 378-383
18. Shakespeare W., Yang M., Bohacek R., Cerasoli F., Stebbins K., Sundaramoorthi R., Azimioara M., Vu C., Pradeepan S., Metcalf III C., Haraldson C., Merry T., Dalgarno D., Narula S., Hatada M., Lu X., Van Schravendijk M.R., Adams S., Violette S., Smith J., Guan W., Bartlett C., Herson J., Iuliucci J., Weigele M., and Sawyer T. Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity. Proc. Natl. Acad. Sci. USA 97 (2000) 9373-9378
19. Liu W.-Q., Vidal M., Olszowy C., Million E., Lenoir C., Dhôtel H., and Garbay C. Structure-activity relationships of small phosphopeptides, inhibitors of Grb2 SH2 domain, and their prodrugs. J. Med. Chem. 47 (2004) 1223-1233
20. Gay B., Suarez S., Caravatti G., Furet P., Meyer T., and Schoepfer J. Selective Grb2 SH2 inhibitors as anti-Ras therapy. Int. J. Cancer 83 (1999) 235-241
21. Song Y.-L., Peach M.L., Roller P.P., Qiu S., Wang S.-M., and Long Y.-Q. Discovery of a novel nonphosphorylated pentapeptide motif displaying high affinity for Grb2-SH2 domain by the utilization of 3′-substituted tyrosine derivatives. J. Med. Chem. 49 (2006) 1585-1596
22. Bradshaw J.M., and Waksman G. Molecular recognition by SH2 domains. Adv. Protein Chem. 61 (2003) 161-210
23. Shakespeare W.C. SH2 domain inhibition: a problem solved?. Curr. Opin. Chem. Biol. 5 (2001) 409-415
24. Oligino L., Lung F.-D.T., Sastry L., Bigelow J., Cao T., Curran M., Burke T.R., Wang S.-M., Krag D., Roller P.P., and King C.R. Nonphosphorylated peptide ligands for the Grb2 Src homology 2 domain. J. Biol. Chem. 272 (1997) 29046-29052
25. Long Y.-Q., Voigt J.H., Lung F.-D.T., King C.R., and Roller P.P. Significant compensatory role of position Y-2 conferring high affinity to non-phosphorylated inhibitors of Grb2-SH2 domain. Bioorg. Med. Chem. Lett. 9 (1999) 2267-2272
26. Li P., Peach M.L., Zhang M., Liu H., Yang D., Nicklaus M., and Roller P.P. Structure based design of thioether-bridged cyclic phosphopeptides binding to Grb2-SH2 domain. Bioorg. Med. Chem. Lett. 13 (2003) 895-899
27. Li P., Zhang M., Long Y.-Q., Peach M.L., Liu H., Yang D., Nicklaus M., and Roller P.P. Potent Grb2-SH2 domain antagonists not relying on phosphotyrosine mimics. Bioorg. Med. Chem. Lett. 13 (2003) 2173-2177
28. Li P., Zhang M., Peach M.L., Zhang X., Liu H., Nicklaus M., Yang D., and Roller P.P. Structural basis for a non-phosphorus-containing cyclic peptide binding to Grb2-SH2 domain with high affinity. Biochem. Biophys. Res. Commun. 307 (2003) 1038-1044
29. Lung F.-D.T., Long Y.-Q., King C.R., Varady J., Wu X.-W., Wang S., and Roller P.P. Functional preference of the constituent amino acid residues in a phage-library-based nonphosphorylated inhibitor of the Grb2-SH2 domain. J. Peptide Res. 57 (2001) 447-454
30. Lou Y.-C., Lung F.-D.T., Pai M.-T., Tzeng S.-R., Wei S.-Y., Roller P.P., and Cheng J.-W. Solution structure and dynamics of G1TE, a nonphosphorylated cyclic peptide inhibitor for the Grb2 SH2 domain. Arch. Biochem. Biophys. 372 (1999) 309-314
31. Mislow K., Green M.M., Laur P., Melillo J.T., Simmons T., and Ternay Jr. A.L. Absolute configuration and optical rotatory power of sulfoxides and sulfinate esters. J. Am. Chem. Soc. 87 (1965) 1958-1976
32. Ottenheijm H.C.J., Liskamp R.M.J., Helquist P., Lauher J.W., and Shekhani M.S. Absolute configuration of sparsomycin. A chiroptical study of sulfoxides. J. Am. Chem. Soc. 103 (1981) 1720-1723
33. Kubec R., and Musah R.A. Cysteine sulfoxide derivatives in, Petiveria alliacea. Phytochemistry 58 (2001) 981-985
34. Liskamp R.M.J., Zeegers H.J.M., and Ottenheijm H.C.J. Synthesis and ring-opening reactions of functionalized sultines. New approach to sparsomycin. J. Org. Chem. 46 (1981) 5408-5413
35. Van den Broek L.A.G.M., Breuer M.L., Liskamp R.M.J., and Ottenheijm H.C.J. Total synthesis and absolute configuration of the natural dipeptide. gamma-glutamylmarasmine. J. Org. Chem. 52 (1987) 1511-1517
36. Frostell-Karlsson A., Remaeus A., Roos H., Andersson K., Borg P., Hamalainen M., and Karlsson R. Biosensor analysis of the interaction between immobilized human serum albumin and drug compounds for prediction of human serum albumin binding levels. J. Med. Chem. 43 (2000) 1986-1992
37. Myszka D.G. Improving biosensor analysis. J. Mol. Recognit 12 (1999) 279-284
38. Mohamadi F., Richards N.G.J., Guida W.C., Liskamp R., and Lipton M. Macromodel-an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J. Comput. Chem. 11 (1990) 440-467
39. Kaminski G.A., Friesner R.A., Tirado-Rives J., and Jorgensen W.L. Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides. J. Phys. Chem. B. 105 (2001) 6474-6487
40. Anil B., Song B., Tang Y., and Raleigh D.P. Exploiting the right side of the Ramachandran plot: substitution of glycines by d-alanine can significantly increase protein stability. J. Am. Chem. Soc. 126 (2004) 13194-13195